	US 12,263,204 B2
	Anti-tumor therapeutic agents based on B7h receptor ligands
Umberto Dianzani, Turin (IT); Casimiro Luca Gigliotti, Novara (IT); Elena Boggio, Mezzomerico (IT); Nausicaa Clemente, Cossato (IT); Annalisa Chiocchetti, Turin (IT); Francesco Trotta, Asti (IT); Roberta Cavalli, Alessandria (IT); and Chiara Dianzani, Turin (IT)
Assigned to NOVAICOS IMMUNOTHERAPEUTICS S.R.L., Colleretto Giacosa (IT)
Appl. No. 16/963,185
Filed by Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Vercelli (IT); and Novaicos S.r.I.s., Novara (IT)
PCT Filed Jan. 9, 2019, PCT No. PCT/IB2019/050154 § 371(c)(1), (2) Date Jul. 17, 2020, PCT Pub. No. WO2019/142070, PCT Pub. Date Jul. 25, 2019.
Claims priority of application No. 102018000001315 (IT), filed on Jan. 18, 2018.
Prior Publication US 2021/0128684 A1, May 6, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 47/69 (2017.01)

CPC A61K 38/1774 (2013.01) [A61K 47/6939 (2017.08); C07K 2319/30 (2013.01)]

21 Claims

1. A method of treatment comprising administering to a subject in need thereof suffering from an established tumor a composition comprising an active agent loaded into or onto a biocompatible micro-or nano-carrier, wherein the active agent consists of a ligand of receptor B7h, wherein the ligand loaded into or onto the biocompatible micro-or nano-carrier is capable of exerting cell toxicity in an in vitro B16-F10 cell viability assay, and wherein the ligand comprises

a) a human ICOS protein having the amino acid sequence as set forth in SEQ ID No.: 1 or a B7h binding portion thereof;

b) a human ICOS extracellular domain having the amino acid sequence as set forth in SEQ ID No.: 2 or a B7h binding portion thereof; or

c) a polypeptide having at least 95% sequence identity to the amino acid sequence of the human ICOS protein or B7h binding portion thereof according to a) or to the amino acid sequence of the human ICOS extracellular domain or B7h binding portion thereof according to b), wherein the polypeptide is capable of binding to receptor B7h.